XL092: Clinical Trials

21 trials of XL092, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 recruiting, 5 not yet recruiting, 1 active not recruiting, 1 terminated. 21 Phase 2, 3 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 221Recruiting 14, Not yet recruiting 5, Active not recruiting 1, Terminated 1
Phase 13Recruiting 2, Terminated 1
Phase 32Active not recruiting 1, Recruiting 1

Follow XL092: new trials by email Literature Review of XL092 trials Research Report on XL092

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zanzalintinib in Unresectable and Progressive MPGGs
Zanzalintinib - Pheochromocytoma, Paraganglioma
Phase 2Not yet recruitingDana-Farber Cancer Institute142027-01-092026-07-20
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Phase 2Not yet recruitingCity of Hope Medical Center342026-11-282026-05-11
Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer
Zanzalintinib - mCRPC (Metastatic Castration-resistant Prostate Cancer)
Phase 2Not yet recruitingStuthi Perimbeti302026-11-012026-11-04
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
Cemiplimab, Zanzalintinib - Anaplastic Thyroid Cancer
Phase 2RecruitingM.D. Anderson Cancer Center122026-10-292026-11-17
A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma
Zanzalintinib - Metastatic Olfactory Neuroblastoma
Phase 2RecruitingM.D. Anderson Cancer Center162026-10-012026-11-10
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
XL092, Pembrolizumab - Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer
Phase 2Not yet recruitingUNC Lineberger Comprehensive Cancer Center262026-09-012026-08-31
Zanzalintinib in Men With Aggressive Variant Prostate Cancer
Zanzalintinib - Aggressive Variant Prostate Carcinoma
Phase 2RecruitingDeepak Kilari302026-08-192026-08-28
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma
Phase 2RecruitingKelly Fitzgerald, MD202026-06-102026-07-27
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Zanzalintinib - Meningioma
Phase 2RecruitingExelixis1002026-05-212026-10-28
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
Phase 2Not yet recruitingOHSU Knight Cancer Institute402026-04-022026-04-06
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Hepatocellular Carcinoma, Cirrhosis
Phase 1 / Phase 2RecruitingDevalingam Mahalingam592026-03-302026-10-23
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
XL092, Nivolumab - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Phase 2RecruitingKarie Runcie702026-03-132026-09-22
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Zanzalintinib - Bone Sarcomas
Phase 2RecruitingM.D. Anderson Cancer Center702025-12-052026-09-25
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
Zanzalintinib, Nivolumab - Locally Advanced Renal Cell Carcinoma
Phase 2RecruitingQian Qin692025-10-302026-09-04
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Zanzalintinib, Everolimus - Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Phase 2 / Phase 3RecruitingExelixis4402025-07-212026-10-30
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Belzutifan, Zanzalintinib - Renal Cell Carcinoma
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC1402025-07-202026-10-27
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma
Phase 2RecruitingJochen Lorch332025-06-062026-06-26
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
XL092 - Metastatic Castration-resistant Prostate Cancer
Phase 2RecruitingUniversity of Utah322024-12-092026-06-29
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Biospecimen Collection, Computed Tomography, Echocardiography - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma
Phase 2RecruitingNorthwestern University732024-09-192026-10-13
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab - Head and Neck Squamous Cell Carcinoma
Phase 2 / Phase 3Active not recruitingExelixis6002024-06-072025-08-17

Showing 20 of 21. Sign in to see all of them.

Conditions studied

Carcinoma, Renal Cell (4)  ·  Bone Neoplasms (2)  ·  Carcinoma, Hepatocellular (2)  ·  Clear-cell metastatic renal cell carcinoma (2)  ·  Neoplasm Metastasis (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Adenocarcinoma, Follicular (1)  ·  Adenoma, Islet Cell (1)  ·  Brain Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Esthesioneuroblastoma, Olfactory (1)  ·  Fibrosis (1)  ·  Head and Neck Neoplasms (1)  ·  Leiomyosarcoma (1)  ·  Meningioma (1)

Sponsors

Exelixis (3)  ·  M.D. Anderson Cancer Center (3)  ·  City of Hope Medical Center (1)  ·  Dana-Farber Cancer Institute (1)  ·  Deepak Kilari (1)  ·  Devalingam Mahalingam (1)  ·  Hoffmann-La Roche (1)  ·  Jochen Lorch (1)  ·  Karie Runcie (1)  ·  Kelly Fitzgerald, MD (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Northwestern University (1)  ·  OHSU Knight Cancer Institute (1)  ·  Qian Qin (1)  ·  Stuthi Perimbeti (1)

Countries

United States (20)  ·  France (4)  ·  South Korea (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Israel (3)  ·  Poland (3)  ·  Austria (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Chile (2)  ·  Germany (2)  ·  Italy (2)  ·  Mexico (2)

Top investigators

Adel Kardosh (1)  ·  Deepak Kilari, MD (1)  ·  Devalingam Mahalingam (1)  ·  Jochen H Lorch (1)  ·  John Livingston, MD (1)  ·  Karie Runcie, MD (1)  ·  Kelly Fitzgerald, MD (1)  ·  Kimbery Perez, MD (1)  ·  Luana Sousa, MD (1)  ·  Pedro Hermida de Viveiros, MD (1)  ·  Qian Qin, MD (1)  ·  Sarah Hamidi, MD (1)  ·  Siddharth Sheth, MD (1)

Results publications

PMID 40248950, PMID 42803451

NIH funding

P30CA060553 (3), 2017 (1), 2025 (1), P30CA033572 (1)